The role of pharmacogenetics in treating central nervous system disorders.
Symptoms of central nervous system (CNS) disorders include abnormalities in both physical and psychological domains. Many drugs indicated for the treatment of CNS disorders are fraught with side effects and/or poor efficacy which impact patients' quality of life and drives non-compliance. Moreover, for many CNS drugs such as antidepressants and antipsychotics, it takes time to determine whether a particular drug is efficacious in an individual patient. To optimize drug treatment for each patient, prescribing physicians often need to raise or lower doses, switch drug classes, or prescribe additional drugs to mitigate side effects, often in a "trial and error" fashion. Pharmacogenetic (PGx) testing, particularly in the realm of CNS therapy, can reduce the unpredictability of this process. By determining a patient's genetic profile, individual therapy parameters may be predicted pre-treatment for drug efficacy, optimal drug dose, and the risk of adverse drug reactions (ADRs). The intent of this review is to highlight the power of PGx testing to predict the likelihood of ADRs and efficacy during the treatment of the following CNS disorders: epilepsy, bipolar disorder, schizophrenia and depression.
PGxHealth, LLC, A Division of Clinical Data, Inc., (NASDAQ: CLDA), 5 Science Park, New Haven, CT 06511, USA. mpatnaik@pgxhealth.com
Meeta
M
Patnaik
Matthew J
MJ
Renda
Maria C
MC
Athanasiou
Carol R
CR
Reed
D002491:Central Nervous System Agents / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000235:genetics; D005544:Forecasting; D006801:Humans; D010597:Pharmacogenetics
D002491:Central Nervous System Agents